Modulating the TGF-β Pathway to Reduce Fibrosis and Enhance Immunity in the Tumor Microenvironment

Time: 3:30 pm
day: Day 2 - PM


• Discussing fibrosis in the context of fibrotic disease and oncology to address the question of antifibrotic mechanism of action and efficacy across diseases
• Initiating thinking on antifibrotics as another checkpoint inhibitor on top of anti-PD1 therapies
• Sharing early thinking on of antifibrotics in oncology, and initial effects reducing parameters of disease activity in late-stage disease